

Summary of status of development and availability of A(H10) candidate vaccine viruses and potency testing reagents

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country

27 September 2024

Candidate vaccine viruses in preparation

Antigenic prototype	Lineage	Туре	Developing Institute	Available from
A/Jiangsu/428/2021 (H10N3)*	Eurasian	Reverse genetics	CDC, USA	Pending

^{*}New CVV shown in blue

Institutes and contact details for candidate vaccine virus orders and other information:

CDC: nmb7@cdc.gov (Subject: CVV request)

WHO CCs: https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-

collaboration-center-erl?CxitPEOtTWx0xUd5TJdODSXcnyJqzYd7FZeivpn7xcl=

Reference antigens (freeze-dried) (to be updated)

	Starting Materials		Ref Ag/		
Parent virus	CVV	Egg or Cell	Lot number	Unitage (μgHA/mL)	Available from

Sheep antisera (to be updated)

Purified HA from		Order		
Parent virus	Egg or Cell	Lot number	Available from	

WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other

information:

CBER/FDA: <u>CBERShippingRequests@fda.hhs.gov</u>

MHRA: <u>standards@mhra.gov.uk</u> or <u>enquiries@mhra.gov.uk</u>

TGA: influenza.reagents@tga.gov.au

For general enquiries, please contact gisrs-whohq@who.int

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses